ARCA biopharma, Inc. (ABIO) saw its loss widen to $4.66 million, or $0.51 a share for the quarter ended Sep. 30, 2016. In the previous year period, the company reported a loss of $2.81 million, or $0.31 a share.

The company has not recorded any revenues for the current as well as previous quarter.

Operating loss for the quarter was $4.71 million, compared with an operating loss of $2.82 million in the previous year period.

"Atrial fibrillation is considered an epidemic cardiovascular disease impacting an estimated 33 million patients globally," commented Dr. Michael Bristow, ARCA's president and chief executive officer "Our on-going GENETIC-AF Phase 2B/3 clinical trial is evaluating GencaroTM as potentially the first genetically-targeted treatment for atrial fibrillation. With the recent enrollment of the 125th patient in the trial, we are approaching two important milestones ��" the enrollment of the 150th patient, anticipated in the first quarter of 2017, and the outcome of the GENETIC-AF Data and Safety Monitoring Board Phase 2B interim efficacy analysis, projected in the third quarter of 2017. We believe there is an unmet medical need for new AF treatments that have fewer side effects than currently available therapies and are more effective, particularly in heart failure with reduced ejection fraction patients."